Q2 2025 · 13F-HR
Merck & Co., Inc. (MRK)holdings as filed
Filed 2025-08-13 · accession 0001691304-25-000005
$215.6M
Reported value
13
Positions
2025-06-30
Period end
The Brief · Merck & Co., Inc. (MRK) · Q2 2025
AI · grounded in 13F
Merck & Co., Inc. (MRK) established a new position in PSNL valued at $92.1M. The fund also initiated new stakes in MRNA for $63.7M and KYMR for $33.7M. Additional new positions include Entrada Therapeutics Inc for $11.7M and ALEC for $5.0M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 71535D106 | PSNL | PERSONALIS INC | $92.1M | 42.7% | 14,044,943 | Common | SHARED |
| 60770K107 | MRNA | MODERNA INC | $63.7M | 29.5% | 2,308,190 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $33.7M | 15.6% | 772,165 | Common | SHARED |
| 29384C908 | TRDA | ENTRADA THERAPEUTICS INC | $11.7M | 5.42% | 1,739,768 | Common | SHARED |
| 014442107 | ALEC | ALECTOR INC | $5.0M | 2.30% | 3,545,719 | Common | SHARED |
| 29970R204 | EVAXUSD | EVAXION BIOTECH A/S | $3.0M | 1.38% | 1,214,126 | Common | SHARED |
| 869367102 | STRO | SUTRO BIOPHARMA INC | $1.9M | 0.90% | 2,723,509 | Common | SHARED |
| N51517105 | 4PKB | LAVA THERAPEUTICS NV | $1.5M | 0.70% | 1,149,345 | Common | SHARED |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $1.3M | 0.61% | 93,414 | Common | SHARED |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $1.0M | 0.47% | 1,483,758 | Common | SHARED |
| 14216R101 | CARM | CARISMA THERAPEUTICS INC | $576,921 | 0.27% | 1,473,240 | Common | SHARED |
| 64136E102 | NEUP | NEUPHORIA THERAPEUTICS INC | $71,192 | 0.03% | 10,027 | Common | SHARED |
| 898920103 | HURA | TUHURA BIOSCIENCES | $31,109 | 0.01% | 13,950 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.